Abstract
Methotrexate (MTX) and vindesine (VDS) have both been found effective in the treatment of acute leukemia. With regard to their pharmacological effects at the cellular level they can reportedly interact. Administration of MTX at high dose levels has been suggested as both a curative and preventive treatment of blastic meningitis. The purpose of this work was to determine whether an injection of VDS leads to any change in MTX clearance and uptake in the cerebrospinal fluid (CSF).
The plasma pharmacokinetic and CSF influx of MTX and VDS were assayed after high dose systemic MTX with an intravenous bolus of VDS administered in the treatment of acute lymphoblastic leukemia. The MTX concentration was determined by enzymatic assay and VDS by radio immunoassay. No interrelation between these drugs was found.
MTX levels in the CSF were sufficient for therapeutic effectiveness but were not affected by intravenous VDS. Detectable amounts of VDS were observed in the CSF but were not altered by MTX.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Freeman A I, Wang J J, Sinks L F: High dose MTX in acute lymphocytic leukemia.Proc Am Assoc Cancer Res 16, 232 (1975).
Green D M, Freeman A I, Sather H N, Sallan S E, Nesbit M E, Cassady T R, Sinks L F, Hammond D, Frei E: Comparison of three methods of CNS prophylaxis in childhood acute lymphoblastic leukemia.Lancet 1, 1398 (1980).
Bayssas M, Gouvera J, Ribaud P, Masset M, De Vassal F, Pico J L, Deluca L, Misset J L, Machover D, Belpomme D, Schwarzenberg L, Jasmin C, Hayat M, Mathe G: Phase II trial of vindesine for regression. Induction in patients with leukemias and hematosarcomas.Cancer Chemother Pharmac 2, 247 (1979).
Chello P L, Sirotnak F M: Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L 1210 leukemia.Cancer Treatment Rep 65, 1049 (1981).
Monjanel S, Rigault J P, Cano J P, Carcassonne Y, Favre R: High dose methotrexate: preliminary evaluation of a pharmacokinetic approach.Cancer Chemother Pharmac 3, 189 (1979).
Bertino J R, Fischer G A: Technics for study of resistance to folic acid antagonists.Methods Med Res 10, 297 (1964).
Root M A, Gerzon K, Dyke R W: Radio immunoassay for vinblastine and vincristine. Abst. 183. Fed. Anal Chem. Spectrosc. Soc. Meeting. October, Indianapolis (1975).
Tan C: Clinical and pharmacokinetic studies of vindesine in 50 children with malignant diseases.Proc 10th Int Congr Chemother, Washington2, 1326 (1978).
Goldman I D, Gupta V, White J C: Exchangeable intra-cellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high dose methotrexate folinic acid rescue protocols.Cancer Res 36, 276 (1976).
Fyle M J, Goldman I D: Characteristics of the vincristine-induced augmentation of methotrexate uptake in ehrlich ascites tumor cells.J Biol Chem 248, 5067 (1973).
Tejada F, Zubrod C G: Vincristine effect on methotrexate cerebrospinal fluid concentration.Cancer Treatment Rep 63, 143 (1979).
Lena N, Imbert A M, Pignon T, Favre R, Meyer G, Cano J P, Carcassonne Y: Methotrexate-vindesine association in the treatment of head and neck cancer. Influence of vindesine on methotrexate’s pharmacokinetic behavior.Cancer Chemother Pharmac 12, 120 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tubiana, N., Lena, N., Barbet, J. et al. Methotrexate-vindesine association in leukemia: Pharmacokinetic study. Med. Oncol. & Tumor Pharmacother. 2, 99–102 (1985). https://doi.org/10.1007/BF02934855
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02934855